A Grey

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. doi request reprint Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 25:2251-5. 2010
  2. doi request reprint Low-dose fluoride in postmenopausal women: a randomized controlled trial
    Andrew Grey
    University of Auckland, Department of Medicine, Private Bag 92019, Auckland, New Zealand
    J Clin Endocrinol Metab 98:2301-7. 2013
  3. doi request reprint The effect of treatments for osteoporosis on mortality
    A Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 24:1-6. 2013
  4. doi request reprint Nonsurgical management of mild primary hyperparathyroidism - a reasonable option
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 77:639-44. 2012
  5. doi request reprint Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland 1142, New Zealand
    Eur J Endocrinol 166:1087-91. 2012
  6. doi request reprint Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Bone 50:1389-93. 2012
  7. pmc Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report
    Mark J Bolland
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1020, New Zealand
    Ann Clin Microbiol Antimicrob 7:3. 2008
  8. ncbi request reprint Emerging pharmacologic therapies for osteoporosis
    Andrew Grey
    University of Auckland, Department of Medicine, Auckland, New Zealand
    Expert Opin Emerg Drugs 12:493-508. 2007
  9. ncbi request reprint Skeletal consequences of thiazolidinedione therapy
    A Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 19:129-37. 2008
  10. ncbi request reprint Thiazolidinedione-induced skeletal fragility--mechanisms and implications
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Diabetes Obes Metab 11:275-84. 2009

Collaborators

Detail Information

Publications54

  1. doi request reprint Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 25:2251-5. 2010
    ..These data demonstrate that the antiresorptive effects of a single 5-mg dose of zoledronate are sustained for 3 years; clinical trials to investigate the antifracture efficacy of dosing intervals longer than 1 year are justified...
  2. doi request reprint Low-dose fluoride in postmenopausal women: a randomized controlled trial
    Andrew Grey
    University of Auckland, Department of Medicine, Private Bag 92019, Auckland, New Zealand
    J Clin Endocrinol Metab 98:2301-7. 2013
    ..Meta-analysis of a heterogeneous dataset of small trials suggests that daily doses of <20 mg fluoride might reduce fracture risk, but it is not known whether low doses of fluoride are safely anabolic to bone...
  3. doi request reprint The effect of treatments for osteoporosis on mortality
    A Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 24:1-6. 2013
    ....
  4. doi request reprint Nonsurgical management of mild primary hyperparathyroidism - a reasonable option
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 77:639-44. 2012
    ..Calcimimetic agents may have a role in managing patients with symptomatic PHPT who cannot undergo, or fail, surgical treatment. There is a need for additional randomized clinical trials to inform management of PHPT...
  5. doi request reprint Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland 1142, New Zealand
    Eur J Endocrinol 166:1087-91. 2012
    ..To determine the effect of pioglitazone on bone marrow fat in humans...
  6. doi request reprint Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Bone 50:1389-93. 2012
    ..Trials assessing the anti-fracture efficacy of dosing intervals of zoledronate of up to 5 years are justified...
  7. pmc Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report
    Mark J Bolland
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1020, New Zealand
    Ann Clin Microbiol Antimicrob 7:3. 2008
    ..People infected with human immunodeficiency virus are frequently treated with medications that can induce or inhibit cytochrome P450 enzymes...
  8. ncbi request reprint Emerging pharmacologic therapies for osteoporosis
    Andrew Grey
    University of Auckland, Department of Medicine, Auckland, New Zealand
    Expert Opin Emerg Drugs 12:493-508. 2007
    ....
  9. ncbi request reprint Skeletal consequences of thiazolidinedione therapy
    A Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 19:129-37. 2008
    ..These observations should prompt clinicians to evaluate fracture risk in patients for whom TZD therapy is being considered, and initiate skeletal protection in at-risk individuals...
  10. ncbi request reprint Thiazolidinedione-induced skeletal fragility--mechanisms and implications
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Diabetes Obes Metab 11:275-84. 2009
    ....
  11. doi request reprint Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    J Clin Endocrinol Metab 97:286-92. 2012
    ..Annual iv administration of 5 mg zoledronate decreases fracture risk. The skeletal effects of annual treatment with doses of zoledronate under 4 mg have not been assessed...
  12. doi request reprint Decreased bone density in men on methadone maintenance therapy
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Addiction 106:349-54. 2011
    ..We sought to determine whether participants in a methadone maintenance programme have evidence of altered bone mineral density (BMD) and bone turnover...
  13. ncbi request reprint The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial
    Andrew Grey
    Department of Medicine, University of Auckland, and LabPlus, Auckland City Hospital, New Zealand
    J Clin Endocrinol Metab 92:1305-10. 2007
    ..Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies...
  14. ncbi request reprint The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Endocrinology 143:4755-63. 2002
    ..These data demonstrate that LPA and S1P potently promote osteoblast survival in vitro, and that cell-type specificity exists in the antiapoptotic signaling pathways activated by phospholipids...
  15. ncbi request reprint Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Endocrinology 144:4886-93. 2003
    ..These data suggest that IGF-I signals osteoblast mitogenesis and survival through parallel, partly overlapping intracellular pathways involving PI-3 kinase, p42/44 MAPKs, and G beta gamma subunits...
  16. ncbi request reprint The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Mol Endocrinol 18:2268-78. 2004
    ....
  17. ncbi request reprint Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Mol Cell Endocrinol 251:96-102. 2006
    ....
  18. ncbi request reprint Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate
    A Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 74:542-50. 2004
    ....
  19. ncbi request reprint Calcium supplementation does not affect CRP levels in postmenopausal women--a randomized controlled trial
    A Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Osteoporos Int 17:1141-5. 2006
    ..Epidemiological studies suggest that calcium supplementation may decrease the risk of cardiovascular disease...
  20. ncbi request reprint Emerging and potential therapies for osteoporosis
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Expert Opin Investig Drugs 14:265-78. 2005
    ....
  21. ncbi request reprint Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases
    A Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Endocrinology 142:1098-106. 2001
    ..However, the LPA mitogenic signal in osteoblastic cells, while requiring G(i) proteins and protein kinase C, is independent of the activity of p42/44 MAP kinases...
  22. ncbi request reprint Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    J Clin Endocrinol Metab 90:2122-6. 2005
    ..Some patients with PHPT may experience an increase in urinary calcium excretion after vitamin D repletion...
  23. doi request reprint The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
    S Bourke
    Department of Rheumatology, Auckland City Hospital, Auckland, New Zealand
    Osteoporos Int 24:349-54. 2013
    ....
  24. doi request reprint Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors
    F Douglas
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 23:2135-40. 2012
    ..Patients require that drug treatments confer substantial fracture risk reductions in order to consider long-term therapy...
  25. doi request reprint Effect of calcium supplementation on hip fractures
    I R Reid
    Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019 Auckland, New Zealand
    Osteoporos Int 19:1119-23. 2008
    ..In addition, those at risk should be looking to other agents with a proven capacity to prevent hip fractures, such as bisphosphonates...
  26. ncbi request reprint Integrating micro CT indices, CT imaging and computational modelling to assess the mechanical performance of fluoride treated bone
    D Sreenivasan
    Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand
    Med Eng Phys 35:1793-800. 2013
    ..The presented computational framework may be used to assess the roles that bone architecture and loading modes play in bone quality, and which micro CT indices are good surrogate measures for mechanical strength...
  27. doi request reprint Cardiovascular effects of calcium supplementation
    I R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Osteoporos Int 22:1649-58. 2011
    ..Since food sources have not been associated with adverse cardiovascular effects, they may be preferable. Available evidence suggests that other osteoporosis treatments are still effective without calcium co-administration...
  28. ncbi request reprint Actions of fibroblast growth factor-8 in bone cells in vitro
    Jian Ming Lin
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Am J Physiol Endocrinol Metab 297:E142-50. 2009
    ..These data suggest that FGF-8 may have a physiological role in bone acting in an autocrine/paracrine manner...
  29. doi request reprint The Auckland calcium study: 5-year post-trial follow-up
    L T Radford
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Osteoporos Int 25:297-304. 2014
    ..There was no increased risk of cardiovascular events after discontinuation of calcium...
  30. ncbi request reprint Evidence for a role for the p110-alpha isoform of PI3K in skeletal function
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Biochem Biophys Res Commun 391:564-9. 2010
    ..Therapeutic agents that target this enzyme have the potential to significantly affect bone homeostasis, and evaluation of skeletal endpoints in clinical trials of such agents is warranted...
  31. ncbi request reprint A potential role for adrenomedullin as a local regulator of bone growth
    D Naot
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Endocrinology 142:1849-57. 2001
    ....
  32. doi request reprint Imatinib mesylate does not increase bone volume in vivo
    Susannah O'Sullivan
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 88:16-22. 2011
    ..These results suggest that, in healthy animals, treatment with imatinib does not increase bone mass and that the improvements in bone density reported in patients receiving imatinib may not be a direct effect of the drug...
  33. pmc Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
    Mark J Bolland
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand
    BMJ 341:c3691. 2010
    ..To investigate whether calcium supplements increase the risk of cardiovascular events...
  34. ncbi request reprint Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Biophys Res Commun 318:240-6. 2004
    ..Our findings are potentially important in refining these peptides for the therapy of osteoporosis...
  35. ncbi request reprint Does calcium supplementation increase cardiovascular risk?
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Clin Endocrinol (Oxf) 73:689-95. 2010
    ....
  36. ncbi request reprint Disparate outcomes from applying U.K. and U.S. osteoporosis treatment guidelines
    Mark J Bolland
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand
    J Clin Endocrinol Metab 95:1856-60. 2010
    ..S.-based National Osteoporosis Foundation (NOF) and the U.K.-based National Osteoporosis Guidelines Group (NOGG) differ markedly in their approaches to treatment recommendations...
  37. ncbi request reprint Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis
    Shyam Sankaran
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    J Clin Endocrinol Metab 95:1653-62. 2010
    ..Uncertainty exists as to the optimal management and monitoring of the skeletal consequences of mild primary hyperparathyroidism (PHPT)...
  38. doi request reprint Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Am J Clin Nutr 91:131-9. 2010
    ..Calcium supplementation has been suggested to have beneficial effects on serum lipids, blood pressure, and body weight, but these possibilities have not been rigorously assessed in men...
  39. ncbi request reprint Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib
    Susannah O'Sullivan
    Department of Medicine, The University of Auckland, Private Bag, Auckland, New Zealand
    J Clin Endocrinol Metab 94:1131-6. 2009
    ..Cross-sectional and short-term prospective studies have demonstrated secondary hyperparathyroidism during imatinib therapy, and variable changes in markers of bone turnover...
  40. ncbi request reprint The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency
    Mark J Bolland
    Osteoporosis Research Group, Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    N Z Med J 121:63-74. 2008
    ..To explore the effects of seasonal variation on the diagnosis of vitamin D sufficiency and to determine whether age, gender, and ethnicity modify these effects...
  41. doi request reprint The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand
    J Clin Endocrinol Metab 94:538-44. 2009
    ..Annual iv administration of 5 mg zoledronate decreases fracture risk. The optimal dosing interval of 5 mg zoledronate is not known...
  42. ncbi request reprint Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective
    Mark Bolland
    Department of Medicine, University of Auckland
    N Z Med J 119:U2339. 2006
    ..The aim of this article is to put the risks of osteonecrosis of the jaw into context with the benefits of bisphosphonate treatment in these clinical scenarios...
  43. doi request reprint Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Arch Intern Med 168:2276-82. 2008
    ..There is no consistent evidence, to our knowledge, that calcium supplementation affects bone mineral density (BMD) in men, despite male osteoporosis being a common clinical problem...
  44. pmc Lactoferrin--a novel bone growth factor
    Dorit Naot
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Clin Med Res 3:93-101. 2005
    ..We conclude that lactoferrin may have a physiological role in bone growth and healing, and a potential therapeutic role as an anabolic factor in osteoporosis...
  45. ncbi request reprint Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms
    Susannah O'Sullivan
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 22:1679-89. 2007
    ....
  46. pmc Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial
    Mark J Bolland
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    BMJ 336:262-6. 2008
    ..To determine the effect of calcium supplementation on myocardial infarction, stroke, and sudden death in healthy postmenopausal women...
  47. ncbi request reprint Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL
    Catherine Middleton-Hardie
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:438-45. 2006
    ..Therefore, correct structure and cellular processing of OPG is essential for normal bone remodeling...
  48. doi request reprint Occult nasal sinus tumours causing oncogenic osteomalacia
    Helen Kenealy
    Department of Endocrinology, Auckland City Hospital, Park Road, Grafton, Auckland, New Zealand
    Eur J Intern Med 19:516-9. 2008
    ....
  49. ncbi request reprint Defining vitamin D deficiency
    Mark J Bolland
    N Z Med J 120:U2760. 2007
  50. ncbi request reprint Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women
    Karl Insogna
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520 8020, USA
    J Bone Miner Res 17:N108-16. 2002
    ..This is because of increased skeletal sensitivity to the resorbing actions of PTH, mediated in part, by the IL-6/IL-6sR cytokine system...
  51. ncbi request reprint Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism
    Andrew Grey
    N Engl J Med 355:2494-5. 2006
  52. pmc Osteonecrosis of the jaw and bisphosphonates: editorial was confusing
    Mark J Bolland
    BMJ 333:1122-3. 2006
  53. ncbi request reprint Bisphosphonates and osteonecrosis of the jaw
    Andrew Grey
    Ann Intern Med 145:791; author reply 792. 2006